The United States has struck a deal with Pfizer to pay the pharmaceutical giant almost $2 billion for 3.7 million more courses of Paxlovid.
“The additional 3.7 million treatment courses are planned for delivery by early 2023,” the company announced.
Pfizer's COVID-19 pill Paxlovid is packaged in Ascoli, Italy, in this undated image. Pfizer/Handout via Reuters
Mimi Nguyen Ly
Reporter
Mimi Nguyen Ly is a former reporter for The Epoch Times.
